CCL4 and lymphoma: IFN-γ KO/KD also did not decrease the efficacy of anti-CD19 CAR Ts against leukemia/lymphoma models, while decreased the levels of some inflammatory cytokines (MCP-1, MIP-1β, IL-6, TNF-α, and IP-10) and macrophage activity markers (CD80 and CD86) [200–202].